1.584EUR-1.74%Mkt Cap: 148.74M EURP/E: —Last update: 2026-06-01
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap148.74M EUR
Enterprise Value139.45M EUR
Revenue (TTM)9.01M EUR
Gross Profit-34.62M EUR
Net Income (TTM)-49.18M EUR
Revenue/Share0.1010 EUR
Last Price1.584 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees164
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010331421
Valuation
P/E (Trailing)—
P/E (Forward)0.75
PEG—
EV/EBITDA-2.62
EV/Revenue15.49
P/S16.81
P/B-6.95
EPS (TTM)-0.55
EPS (Forward)2.15
52W Range
1.03047% of range2.200
52W High2.200 EUR
52W Low1.030 EUR
Profitability
Gross Margin0.00%
Oper. Margin-689.55%
EBITDA Margin0.00%
Profit Margin-1764.51%
ROE226.58%
ROA-78.41%
Growth
Revenue Growth-46.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.56M EUR
CapEx (TTM)2.35M EUR
FCF Margin-378.39%
FCF Yield-22.91%
Net Debt-11.74M EUR
Net Debt/EBITDA0.22
Balance Sheet
Debt/Equity-1.04
Current Ratio1.27
Quick Ratio1.14
Book Value/Sh-0.2320 EUR
Cash/Share0.3660 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.350 EUR
Target Range4.500 EUR – 6.200 EUR
# Analysts2
Ownership
Shares Out.93.90M
Float65.91M
Insiders25.70%
Institutions8.17%
Technical
SMA 501.308 (+21.1%)
SMA 2001.540 (+2.9%)
Beta0.81
S&P 52W Chg27.94%
Avg Vol (30d)602.88K
Avg Vol (10d)1.10M
Technical Indicators
RSI (14)55.7
MACD0.0894
MACD Signal0.1058
MACD Hist.-0.0164
BB Upper2.025 EUR
BB Middle1.520 EUR
BB Lower1.015 EUR
BB Width66.43%
ATR (14)0.1532 EUR
Vol Ratio (20d)1.43x